Alpha Hormones publishes more than a general statement that it treats menopause. Its treatment menu names FDA-approved oral micronized progesterone, while its pricing page describes a broader women’s hormone program. Those details establish a relevant offering, but the program’s name and inclusions cannot explain why a particular patient would need each medicine.

We reviewed Alpha’s treatment, price and subscription information on September 29, 2026. This assessment focuses on how a reader can separate a package description from a clinical purpose. It also preserves the program’s published geographic and consultation limits. No appointment was tested, and no exact manufacturer, personal prescription or individual insurance benefit is established here.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Alpha Hormones menopause review: what a combined program does and does not explain — keep the exact product identity and its complete label together.

A named oral option does not settle the whole plan

Alpha’s BHRT page mentions FDA-approved oral micronized progesterone and separately describes compounded options. That distinction is useful, but it does not establish which one a clinician would select or the manufacturer of a supplied product. The women’s program discusses several hormones; listing them together does not mean every participant should receive all of them. The systemic estrogen guide explains why the purpose of an added medicine deserves its own discussion. A product’s approval status also does not establish suitability for every person who seeks menopause care or every use for which a clinician might consider it.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
A named oral option does not settle the whole plan — keep the exact product identity and its complete label together.

Geographic access is part of the actual offer

The pricing and access information advertises care for residents of California, Texas and Florida, together with an in-person option in Pasadena. Those are meaningful boundaries rather than evidence of unrestricted US availability. They do not guarantee a specific appointment, prescribing decision or ongoing service after a move. Fountain’s review considers a different platform and medical-group arrangement, making it useful to compare who provides care and how a reader qualifies for that relationship. Alpha’s general insurance descriptions should likewise be kept separate from confirmation of a person’s benefits, network status, deductible or coverage of the selected prescription.

The clinical question is more specific than hormone balance

The BMS endometrial-protection tool describes a particular role for progestogens in relevant estrogen treatment. That role cannot be assumed from a program’s general promise of hormone optimization. Conversely, the NAMS low-dose vaginal estrogen statement says a progestogen is not indicated in that defined context, while noting that clinical trials had not assessed endometrial safety beyond one year. Those are qualified clinical statements, not a self-directed selection rule. The local estrogen guide helps distinguish the question from systemic treatment. Alpha’s public pages do not tell us which category an unidentified existing medicine belongs to or what an individual assessment would conclude.

Editorial illustration: two consultation chairs and a notebook on a side table.
The clinical question is more specific than hormone balance — bring the unanswered questions into the appropriate professional conversation.

The monthly and annual prices retain a setup charge

Alpha’s published program prices start at $349 per month or $3,490 per year, with a one-time $200 setup fee. Consultations, tailored laboratory work, medications, supplies and free shipping are described as included, but additional services or items may incur out-of-pocket costs. Those starting figures are not an exact quote for every patient or a specific capsule. A written estimate should identify the chosen arrangement and any excluded work. Newson Clinic, a UK service charging for defined appointments, provides a different comparison model; its pound-denominated consultation prices cannot be treated as substitutes for this US program’s full recurring cost.

An included consultation has a published unit

Alpha’s subscription policy limits the consultation included in each month after the first to one fifteen-minute telehealth or in-person consultation. That unit matters alongside a general statement that visits are included. It does not show whether an extra assessment, investigation or longer discussion would be covered. The same policy separates automatic billing from medication refills: refills require a patient request and are not automatically sent merely because another charge occurs. For the uterus question, the practical issue is who reassesses the medicine’s purpose if circumstances change. A recurring payment and a short included visit cannot, by themselves, establish that the needed clinical work has occurred.

Editorial illustration: a telehealth screen, a question card and an unbranded container.
An included consultation has a published unit — keep the product information and the route for asking a question in the same comparison.

History and changed symptoms may require a different discussion

The BMS endometriosis guidance illustrates why even a hysterectomy history needs interpretation: some post-hysterectomy circumstances can lead to consideration of combined treatment, with residual disease, individual risks and limited evidence shaping the decision. This review does not establish that Alpha follows that UK guidance or how its clinicians assess a given history. The hysterectomy questions guide offers background for asking. Separately, NHS advice is to have postmenopausal bleeding checked, even a small one-off episode. A reader should not infer its cause or wait for the next billing cycle because a program already includes hormones.

Closing an account and changing care are separate matters

The published cancellation policy asks for written notice thirty days before the next billing date and describes limits on prorated subscription refunds and medicine returns. These are the provider’s purchase conditions, not a generalized legal rule or confirmation of a particular refund outcome. They also do not instruct a patient how to change a treatment plan. The unexpected bleeding guide keeps clinical assessment separate from administrative questions. Alpha’s documented service can be considered on its own terms, but the unresolved clinical task remains an explanation of the actual medicine, the intended goal and who takes responsibility for reassessment beyond routine billing and refill requests.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. Alpha Hormones: Bioidentical hormone replacement therapyProvider treatment menu naming FDA-approved oral micronized progesterone and separately compounded options; no exact prescribed product confirmed · Checked 2026-09-29
  2. Alpha Hormones: PricingProvider program starting prices, setup fee, access and insurance descriptions; individual selection and benefits remain unverified · Checked 2026-09-29
  3. British Menopause Society: Progestogens and endometrial protectionUK professional clinical tool, internally reviewed February 2026; May 2026 is the URL/file version, not the stated review month. Preparation-specific evidence and endometrial-protection limits, with no dose or schedule instructions reproduced · Checked 2026-09-29
  4. NAMS: The 2020 genitourinary syndrome of menopause position statement — abstractPublished professional consensus abstract only; low-dose vaginal estrogen distinction retains absent endometrial-safety clinical trials beyond one year, not a complete-paper or individualized assessment · Checked 2026-09-29
  5. Alpha Hormones: Subscription cancellation policyProvider recurring billing, refill-request and cancellation/return conditions; attributed purchase policy, not generalized legal advice · Checked 2026-09-29
  6. British Menopause Society: Induced menopause in women with endometriosis, February 2026UK professional clinical tool, February 2026; post-hysterectomy exceptions depend on residual disease and individual risks, with limited high-quality evidence and case-by-case decisions · Checked 2026-09-29
  7. NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29
Read our editorial method →